The UTOPIA trial focused on Japanese individuals with uncontrolled T2DM (HbA1c ≥ 6% and < 9%), resistant to diet, exercise or medication, excluding recent SGLT‐2 inhibitor users. Here, SLC5A2 is linked to type 2 diabetes mellitus.